$26.41−0.22 (−0.83%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Stoke Therapeutics (STOK) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
46 figures withheld by our checks. Each blank figure names its reason.
Business engineGrowing fast: revenue compounds ~145.9%/yr (FY22→FY25), net margin −3.7%. Worth your attention in FY25: Share count (+61.2%) and Capex step-up ($670.0K). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲404.5%
184.4
FY22→FY25CAGR +145.9%/yr
Net income ($M)▲92.3%
−6.9
FY21→FY25CAGR —
Free cash flow ($M)—
44.9
capex stepped upCAGR —
Diluted EPS▲92.7%
−0.12
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+61.2%
36.7mn → 59.2mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$670.0K
▲230% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-4¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Operating Net
Net margin -3.7% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 28,211.0 | 184,420.0 | 36,555.0 | 8,780.0 | 12,405.0 | 0.0 | ▲404.5% | +145.9% (22→25) |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | —A | —A | —A | —A | —A | 0.0 | — | — |
Research & development | 190,700.0 | 137,922.0 | 89,133.0 | 82,231.0 | 77,837.0 | 54,168.0 | ▲54.7% | +26.3% |
Selling, general & admin | 95,112.0 | 67,088.0 | 48,794.0 | 41,322.0 | 38,924.0 | 31,897.0 | ▲37.5% | +20.4% |
Total operating expenses | 285,812.0 | 205,010.0 | 137,927.0 | 123,553.0 | 116,761.0 | 86,065.0 | ▲48.6% | +24.2% |
Operating incomefeeds ROC rank | −257,601.0 | −20,590.0 | −101,372.0 | −114,773.0 | −104,356.0 | −86,065.0 | ▲79.7% | — |
Other income, net | 14,402.0 | 13,705.0 | 12,391.0 | 10,074.0 | 3,289.0 | 260.0 | — | — |
Pretax income | −243,199.0 | −6,885.0 | −88,981.0 | −104,699.0 | −101,067.0 | −85,805.0 | ▲92.3% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −243,199.0 | −6,885.0 | −88,981.0 | −104,699.0 | −101,067.0 | −85,805.0 | ▲92.3% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −3.77 | −0.12 | −1.65 | −2.38 | −2.60 | −2.34 | ▲92.7% | — |
Diluted shares (mn) | 68.36 | 59.22 | 54.01 | 43.99 | 38.90 | 36.74 | ▲9.6% | +12.7% |
| Margins | ||||||||
Gross margin | —A | —A | —A | —A | —A | — | — | — |
Operating margin | −913.1% | −11.2% | −277.3% | −1307.2% | −841.2% | — | ▲266.1pp | +830.1pp |
Net margin2nd pct in Healthcare | −862.1% | −3.7% | −243.4% | −1192.5% | −814.7% | — | ▲239.7pp | +811.0pp |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-16 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Stoke Therapeutics' revenue last fiscal year?
Stoke Therapeutics reported revenue of $184.4M in fiscal 2025, up 404.5% from fiscal 2024.
What was Stoke Therapeutics' net income?
Stoke Therapeutics reported net income of −$6.9M in fiscal 2025, a net margin of −3.7%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

